DNA hypo-methylation of the TNFA gene predicts response to MTX in RA but not in PsA
Authors:
- Elisa DalixEDElisa Dalix
- Rujiraporn PitaksaleeRPRujiraporn Pitaksalee
- Gabriele De MarcoGMGabriele De Marco
- Farag ShuweihdiFSFarag Shuweihdi
- Sarah R KingsburySKSarah R Kingsbury
- Helena Marzo-OrtegaHMHelena Marzo-Ortega
- Philip G ConaghanPCPhilip G Conaghan
- Paul EmeryPEPaul Emery
- Hubert MarotteHMHubert Marotte
- 28 August 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Abstract
Objectives: The ‘Treat-to-Target’ approach significantly improves treatment outcomes in RA and PsA (RA/PsA). MTX is commonly used as a first-line treatment upon diagnosis. However, 50–70% of treated patients do not achieve clinical remission after 6 months. We previously developed a quantitative methylation-sensitive qPCR (qMSP) assay to quantify DNA-methylation levels of the TNFA gene. We demonstrated its predictive value for RA diagnosis. Here, we assessed the utility of this qMSP assay for predicting MTX treatment outcome and investigated changes in DNA-methylation levels after 6 months of MTX. Methods: Early untreated RA (n = 201) and PsA (n = 77) were included with healthy controls (n = 39). The TNFA-qMSP assay was performed by qPCR on bisulphite-converted DNA extracted from frozen peripheral blood mononuclear cells. The outcome predictive-value of DNA-methylation levels was analysed using binary logistic regression and area under the curve (AUC). Results: Pre-treatment DNA-methylation levels of the TNFA gene were reduced in RA (P = 1.8 × 10−13) and PsA (P = 0.007) compared with controls. Higher DNA-methylation levels were associated with MTX-induced remission in RA (AUC = 0.721) and substantially improved the performance of a predictive model when combined with clinical data (AUC = 0.760) compared with clinical data only (AUC = 0.699). Levels of methylation reduced over time, irrespective of response to MTX in RA. In PsA, DNA-methylation levels were not associated with treatment outcome. Conclusion: The TNF qMSP assay has potential clinical utility as a biomarker for predicting MTX-induced remission specifically in early RA, but not in PsA. However, MTX does not appear to prevent the reduction of DNA-methylation levels at the TNFA loci over time.Keywords
Funding Information
- Royal Thai Government Scholarship
- National Institute on Handicapped Research
- Leeds Biomedical Research Centre
- National Health Service
This publication has 39 references indexed in Scilit:
- Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2015
- The Th17 axis in psoriatic disease: pathogenetic and therapeutic implicationsAutoimmunity Highlights, 2014
- DNA hypomethylation in inflammatory arthritis: Reversal with methotrexateJournal of Laboratory and Clinical Medicine, 1996
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994
- Mechanisms of Methotrexate Action in Rheumatoid ArthritisArthritis & Rheumatism, 1994
- Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexateRheumatology International, 1992
- The in vitro effects of methotrexate on peripheral blood mononuclear cells: Modulation by methyl donors and spermidineArthritis & Rheumatism, 1990
- Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexateInternational Journal of Immunopharmacology, 1988
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987
- Immunologic studies of rheumatoid arthritis patients treated with methotrexateArthritis & Rheumatism, 1987